Is Bosulif Approved for Philadelphia Chromosome-Positive CML?
Yes, Bosulif (bosutinib) is FDA-approved to treat chronic myeloid leukemia (CML) that is Philadelphia chromosome-positive (Ph+). It targets adults with chronic, accelerated, or blast phase Ph+ CML, including newly diagnosed chronic phase patients and those resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy.[1]
How Does Bosulif Work in Ph+ CML?
Bosutinib is a second-generation TKI that inhibits the BCR-ABL fusion protein created by the Philadelphia chromosome (t(9;22) translocation). This blocks cancer cell growth signals in Ph+ CML. Clinical trials showed 84% of newly diagnosed chronic phase patients achieved major cytogenetic response (≤35% Ph+ metaphases) by 12 months.[1][2]
When Is Bosulif Used in CML Treatment?
- First-line: Approved since 2017 for newly diagnosed chronic phase Ph+ CML, after showing non-inferiority to imatinib in response rates.
- Later-line: Original 2012 approval for chronic, accelerated, or blast phase Ph+ CML after failure of prior TKIs like imatinib.
Dosing starts at 400 mg daily for chronic phase, adjusted for intolerance.[1]
How Does Bosulif Compare to Other TKIs for Ph+ CML?
| Drug | Generation | First-Line Approval | Key Response Data (New Chronic Phase) |
|------|------------|---------------------|---------------------------------------|
| Imatinib (Gleevec) | 1st | Yes | ~70% major cytogenetic response at 12 months |
| Dasatinib (Sprycel) | 2nd | Yes | ~80-85% |
| Nilotinib (Tasigna) | 2nd | Yes | ~80% |
| Bosutinib (Bosulif) | 2nd | Yes | 84% [1][2] |
Bosulif offers similar efficacy but may have a distinct side effect profile, with less pleural effusion than dasatinib but more diarrhea.[2]
What Side Effects Do Bosulif Patients Experience?
Common issues include diarrhea (70-80% of patients), nausea, and rash. Serious risks: liver toxicity (monitor ALT/AST), QT prolongation, and fluid retention. In trials, 20-25% discontinued due to adverse events.[1]
When Does Bosulif's Patent Protection End?
Key U.S. patents for bosutinib expire in 2029-2034, depending on formulation and method-of-use claims. No biosimilars are approved yet, but challenges are ongoing via FDA's 505(b)(2) pathway.[3]
Sources
[1]: FDA Label for Bosulif
[2]: NEJM: Bosutinib vs Imatinib in Newly Diagnosed CML
[3]: DrugPatentWatch: Bosutinib Patents